Initiation Archives - Page 229 of 272

1 minute read

Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says

August 29, 10:49 AM

Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities.

XENE

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 29, 2022

By Benzinga Insights

August 29, 10:11 AM

Upgrades

AERI

1 minute read

Cantor Fitzgerald Initiates Coverage On Mondee Hldgs with Overweight Rating, Announces Price Target of $15

By Benzinga Newsdesk

August 29, 9:23 AM

Cantor Fitzgerald analyst Brett Knoblauch initiates coverage on Mondee Hldgs (NASDAQ:MOND) with a Overweight rating and announces Price Target of $15.

MOND

1 minute read

Roth Capital Initiates Coverage On Battalion Oil with Buy Rating, Announces Price Target of $28

By Benzinga Newsdesk

August 29, 9:21 AM

Roth Capital analyst John White initiates coverage on Battalion Oil (AMEX:BATL) with a Buy rating and announces Price Target of $28.

BATL

1 minute read

Maxim Group Initiates Coverage On Cryo-Cell International with Buy Rating, Announces Price Target of $12

By Benzinga Newsdesk

August 29, 8:48 AM

Maxim Group analyst Allen Klee initiates coverage on Cryo-Cell International (NASDAQ:CCEL) with a Buy rating and announces Price Target of $12.

CCEL

1 minute read

CL King Initiates Coverage On Denny’s with Buy Rating, Announces Price Target of $14

By Benzinga Newsdesk

August 29, 8:45 AM

CL King analyst Andrew Wolf initiates coverage on Denny's (NASDAQ:DENN) with a Buy rating and announces Price Target of $14.

DENN

1 minute read

Dawson James Initiates Coverage On Smart for Life with Buy Rating, Announces Price Target of $8

By Benzinga Newsdesk

August 29, 8:43 AM

Dawson James analyst Jason Kolbert initiates coverage on Smart for Life (NASDAQ:SMFL) with a Buy rating and announces Price Target of $8.

SMFL

1 minute read

B of A Securities Initiates Coverage On IGM Biosciences with Buy Rating, Announces Price Target of $34

By Benzinga Newsdesk

August 29, 8:40 AM

B of A Securities analyst Geoff Meacham initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Buy rating and announces Price Target of $34.

IGMS

1 minute read

Cowen & Co. Initiates Coverage On Deciphera Pharmaceuticals with Outperform Rating, Announces Price Target of $25

By Benzinga Newsdesk

August 29, 6:29 AM

Cowen & Co. analyst Tyler Van Buren initiates coverage on Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform rating and announces Price Target of $25.

DCPH